INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE
Product details
Registration number: SIN14853P
Classification: Prescription Only
Active ingredients: Umeclidinium Bromide 74.2 mcg (micronised) eqv. Umeclidinium
Strength: 62.5 mcg/dose
Dosage form: POWDER, METERED
Route: RESPIRATORY (INHALATION)
Registrant: GLAXOSMITHKLINE PTE LTD
ATC code: R03BB07
HSA approval date: 21 September 2015
Manufacturer(s):
- Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations)
- GlaxoSmithKline LLC
Manufacturing country/countries: UNITED STATES; UNITED KINGDOM
What are the HSA registration number and classification for INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN14853P
Classification: Prescription Only
What active ingredients and strength are recorded for INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE?
According to the HSA dataset updated 7 August 2026:
Active ingredients: Umeclidinium Bromide 74.2 mcg (micronised) eqv. Umeclidinium
Strength: 62.5 mcg/dose
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE?
According to the HSA dataset updated 7 August 2026:
Dosage form: POWDER, METERED
Route: RESPIRATORY (INHALATION)
Who is the recorded registrant for INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE?
According to the HSA dataset updated 7 August 2026:
Registrant: GLAXOSMITHKLINE PTE LTD
Which manufacturers and countries are listed for INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s):
- Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations)
- GlaxoSmithKline LLC
Manufacturing country/countries: UNITED STATES; UNITED KINGDOM
Where can I look up INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN14853P or the exact product name INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE. The general register link does not preselect this product.
What are the source dates for this INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN14853P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)